Elevation Oncology licenses ADC Technology from Synaffix to drive pipeline expansion
Amsterdam, The Netherlands, 12 December 2024 — Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (adcs) with best-in-class therapeutic index, today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
Synaffix gives Elevation Oncology global access to its clinical stage, site-specific ADC technology platform, including glycoconnect® antibody conjugation technology, hydraspace® polar spacer technology, as well as the toxsyn® linker-payload, synstatin E™, which enables the transformation of Elevation Oncology’s antibody into a differentiated ADC with best-in-class potential.
Under the terms of the agreement, Synaffix is eligible to receive up to USD 368 million in upfront and clinical, regulatory, and commercial milestone payments, plus tiered royalties on net sales. Synaffix is responsible for manufacturing the components related to its proprietary technologies, and Elevation Oncology is responsible for the research, development, manufacturing, and commercialization of the ADC.
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace®, and toxSYN® technologies. Together, these technologies enable any company with an antibody to develop proprietary, best-in-class ADC products under a single licence from Synaffix.
Read the full press release here.
Find more news here.